Novocure to Participate in 2024 Wells Fargo Healthcare Conference
August 28 2024 - 7:00AM
Business Wire
Novocure (NASDAQ: NVCR) announced today that management will
participate in the 2024 Wells Fargo Healthcare Conference on
Wednesday, September 4, 2024. William Doyle, Novocure’s Executive
Chairman, will take part in a fireside chat at 4:30 p.m. EST, as
well as one-on-one meetings with investors throughout the
event.
A live audio webcast of this presentation can be accessed from
the Investor Relations page of Novocure’s website,
www.novocure.com/investor-relations, and will be available for
replay for at least 14 days following the event.
Novocure’s corporate presentation is updated periodically, and
the current presentation can be accessed from the Investor
Relations page of Novocure’s website,
www.novocure.com/investor-relations. Novocure has used, and intends
to continue to use, its Investor Relations website as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions and other more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2024, and subsequent
filings with the U.S. Securities and Exchange Commission. Given
these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not
rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof.
The Private Securities Litigation Reform Act of 1995 permits this
discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828606784/en/
INVESTORS: Ingrid Goldberg investorinfo@novocure.com
MEDIA: Catherine Falcetti media@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Oct 2024 to Oct 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Oct 2023 to Oct 2024